Clinical Scorecard: Case Study: IgG4-Related Disease Induced by Immune Checkpoint Inhibitors Resembling Renal Metastatic Progression: Effective Management with Rituximab and Reduced Steroid Use
At a Glance
Category
Detail
Condition
IgG4-Related Disease (IgG4-RD)
Key Mechanisms
Induced by immune checkpoint inhibitors leading to fibroinflammatory autoimmune manifestations.
Target Population
Patients with metastatic clear cell renal carcinoma treated with dual immune checkpoint inhibitors.
Care Setting
Oncology and nephrology settings.
Key Highlights
IgG4-RD can mimic metastatic progression in patients receiving immune checkpoint inhibitors.
Histologic confirmation is crucial for accurate diagnosis.
Rituximab may be an effective treatment strategy while preserving antitumor immunity.
The case emphasizes the importance of recognizing rare immune-related adverse events.
Guideline-Based Recommendations
Diagnosis
Histopathological examination is essential for confirming IgG4-RD.
Management
Rituximab is recommended as a steroid-sparing first-line therapy.
Monitoring & Follow-up
Regular imaging and clinical evaluation to assess disease progression and treatment response.
Risks
Potential for misdiagnosis as metastatic disease without proper histological assessment.
Patient & Prescribing Data
A 65-year-old man with metastatic clear cell renal carcinoma.
Two infusions of rituximab (1000 mg each) led to radiologic stabilization/regression of renal lesions.
Clinical Best Practices
Consider IgG4-RD in patients presenting with renal lesions post-ICI therapy.
Avoid glucocorticoids if antitumor immune response preservation is a priority.
by Mayara Elisa Bonatto, Jan Dvořák, Marek Kollár, David Girsa, Miroslav Průcha, Šárka Forejtová, Heřman Mann, Jiří Vencovský, Karel Pavelka, Ladislav Šenolt
